Shopping Cart

Your shopping cart is currently empty

Aranidipine

Name: Aranidipine
Brand: TargetMol
SKU: T5376
Price: 38 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T5376Cas No. 86780-90-7

Alias MPC1304

Aranidipine (MPC1304) (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects.

Aranidipine

Copy Product Info

🥰Excellent

Purity: 99.15%

Catalog No. T5376Alias MPC1304Cas No. 86780-90-7

Aranidipine (MPC1304) (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects.

Pack Size	Price	USA Warehouse	Global Warehouse
10 mg	$38	In Stock	In Stock
25 mg	$74	In Stock	In Stock
50 mg	$118	In Stock	In Stock
100 mg	$178	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.15%

Appearance:Solid

Color:White

Resource Download

COA HPLC HNMR LCMS

Product Introduction

Bioactivity

Description	Aranidipine (MPC1304) (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects.
In vitro	In myocytes, aranidipine (10 nmol/l to 1 micromol/l) concentration-dependently decreased T-type and L-type Ca(2+) currents. Aranidipine (1 micromol/l) had little effect on K(+) currents. In the sinoatrial node, 0.1 micromol/l aranidipine increased cycle length and decreased +V(max) and the slope of the phase 4 depolarization [1].
In vivo	At 1 and 6 h after oral administration of MPC-1304 (10 mg/kg) in spontaneously hypertensive rats (SHR), there was significant decrease (48%) in the number of [3H](+)-PN 200-110 binding sites (Bmax) in myocardial membranes compared to control values. The in vivo specific binding of [3H](+)-PN 200-110 in particulate fractions of aorta of SHR was significantly reduced (74.8 and 37.9%, respectively) at 1 and 6 after oral administration of MPC-1304 (3 mg/kg), while the myocardial [3H](+)-PN 200-110 binding was decreased only at 1 h later [2].
Synonyms	MPC1304

Chemical Properties

Molecular Weight	388.37
Formula	C₁₉H₂₀N₂O₇
Cas No.	86780-90-7
Smiles	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)=O
Relative Density.	1.284 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 22.5 mg/mL (57.93 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.15 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.5749 mL	12.8743 mL	25.7486 mL	128.7432 mL
5 mM	0.5150 mL	2.5749 mL	5.1497 mL	25.7486 mL
10 mM	0.2575 mL	1.2874 mL	2.5749 mL	12.8743 mL
20 mM	0.1287 mL	0.6437 mL	1.2874 mL	6.4372 mL
50 mM	0.0515 mL	0.2575 mL	0.5150 mL	2.5749 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc